1. Home
  2. PHVS vs WOR Comparison

PHVS vs WOR Comparison

Compare PHVS & WOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • WOR
  • Stock Information
  • Founded
  • PHVS 2015
  • WOR 1955
  • Country
  • PHVS Switzerland
  • WOR United States
  • Employees
  • PHVS N/A
  • WOR N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • WOR Aerospace
  • Sector
  • PHVS Health Care
  • WOR Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • WOR Nasdaq
  • Market Cap
  • PHVS 1.3B
  • WOR 3.3B
  • IPO Year
  • PHVS 2021
  • WOR N/A
  • Fundamental
  • Price
  • PHVS $24.54
  • WOR $62.74
  • Analyst Decision
  • PHVS Strong Buy
  • WOR Buy
  • Analyst Count
  • PHVS 5
  • WOR 3
  • Target Price
  • PHVS $35.60
  • WOR $63.67
  • AVG Volume (30 Days)
  • PHVS 144.5K
  • WOR 195.2K
  • Earning Date
  • PHVS 11-12-2025
  • WOR 09-23-2025
  • Dividend Yield
  • PHVS N/A
  • WOR 1.08%
  • EPS Growth
  • PHVS N/A
  • WOR N/A
  • EPS
  • PHVS N/A
  • WOR 1.92
  • Revenue
  • PHVS N/A
  • WOR $1,153,762,000.00
  • Revenue This Year
  • PHVS N/A
  • WOR $13.63
  • Revenue Next Year
  • PHVS N/A
  • WOR $4.73
  • P/E Ratio
  • PHVS N/A
  • WOR $32.73
  • Revenue Growth
  • PHVS N/A
  • WOR N/A
  • 52 Week Low
  • PHVS $11.51
  • WOR $37.88
  • 52 Week High
  • PHVS $26.33
  • WOR $70.91
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 60.91
  • WOR 44.78
  • Support Level
  • PHVS $23.20
  • WOR $62.72
  • Resistance Level
  • PHVS $24.02
  • WOR $65.69
  • Average True Range (ATR)
  • PHVS 1.37
  • WOR 1.52
  • MACD
  • PHVS 0.08
  • WOR -0.47
  • Stochastic Oscillator
  • PHVS 84.66
  • WOR 29.28

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About WOR Worthington Enterprises Inc.

Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.

Share on Social Networks: